Skip to main content

Table 3 HU-related treatment patterns associated with patients who discontinued and those who did not

From: Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

  Currently using HU therapy (n = 1080) Discontinued HU therapy (n = 229)
Years diagnosed with PV   
 n 1080 229
 Mean ± SD 5.23 ± 2.77 5.25 ± 2.82
Duration of HU therapy for current users, mo   
 n 1080
 Mean ± SD 46.97 ± 30.83
Duration of HU therapy before discontinuation, mo   
 n 229
 Mean ± SD 23.19 ± 24.45
Current HU dose, mg/d   
 n 1055
 Mean ± SD 984.2 ± 673.6
 Median (q25–q75) 1000.0 (500.0–1000.0)
Last dose of HU before discontinuation, mg/d   
 n 225
 Mean ± SD 990.9 ± 689.3
 Median (q25–q75) 1000.0 (500.0–1200.0)
Highest ever HU dose, mg/d   
 n 491 123
 Mean ± SD 1413.0 ± 875.5 1443.6 ± 876.4
 Median (q25–q75) 1000.0 (1000.0–2000.0) 1000.0 (1000.0–2000.0)
Lowest ever HU dose, mg/d   
 n 503 125
 Mean ± SD 745.1 ± 576.8 744.0 ± 437.9
 Median (q25–q75) 500.0 (500.0–1000.0) 500.0 (500.0–1000.0)
Most stable HU dose, mg/d   
 n 468 114
 Mean ± SD 1129.8 ± 742.2 1167.2 ± 781.7
 Median (q25–q75) 1000.0 (712.5–1500.0) 1000.0 (500.0–1500.0)
Number of HU dose adjustments in 3 mo before discontinuation   
 n 205
 Mean ± SD 0.48 ± 1.06
  1. HU hydroxyurea, PV polycythemia vera